Bio-Rad Laboratories, Inc. (BIO) Launches New Digital PCR Systems in 2025

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new digital PCR system.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the most undervalued healthcare stocks. It is a global leader in life science research and clinical diagnostics and advanced its digital PCR capabilities in 2025 with the launch of four new Droplet Digital PCR (ddPCR) instruments, including the QX Continuum and QX700 series, acquired through its purchase of Stilla Technologies. These systems significantly expand the company’s ddPCR portfolio, now offering over 400,000 assays, and enhance applications in oncology, infectious disease, and genetic analysis through improved multiplexing, throughput, and workflow integration.

Supporting the growing field of gene therapy, Bio-Rad Laboratories, Inc. (NYSE:BIO) released ddPCR kits for accurate measurement of adeno-associated virus (AAV) vectors, enabling efficient viral titer and capsid integrity assessment. The company also extended its Vericheck kits to support additional viral serotypes for broader biotherapeutic research.

The corporation’s other key product launches include the TrailBlazer Tag and StarBright Dye Label kits for antibody conjugation in flow cytometry and Western blotting, and new purification tools—Nuvia wPrime 2A resin and Foresight Pro columns, designed for scalable biopharma manufacturing.

Throughout 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) has remained actively engaged in global industry events, offering workshops on diagnostic innovation and showcasing its expanding technology portfolio for both clinical and research applications.

While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.